Literature DB >> 86634

Human tumor-lymphocyte interaction in vitro. VI. Specificity of primary and secondary autologous lymphocyte-mediated cytotoxicity.

F T Vánky, B M Vose, M Fopp, E Klein.   

Abstract

A T-cell-enriched lymphocyte subset of samples from 15 tumor patients was tested for primary cytotoxicity against autologous tumor cell preparations and against 1-3 different allogeneic tumor cell preparations from biopsy material. Allogeneic cytotoxicity occurred in only 1 of 10 patients with autologous reactivity. The lymphocytes of 14 patients were cultured with autologous cells from biopsy material for 6 days. These lymphocytes killed autologous targets, but only 1 patient's lymphocytes were cytotoxic against 1 of the 4 allogeneic tumors tested. Cocultivation with allogeneic cells from biopsy specimens generated cytotoxicity toward the sensitizing allogeneic cells in 3 of 9 test combinations. In 2 of 3 instances the effectors were also active against the autologous tumor cells. Cytotoxicity in primary and secondary tests occurred thus only rarely against allogeneic targets. This indicated either the presence of individual tumor-related antigens on the cells from biopsy material or reflected the histocompatibility restriction of T-cell-mediated cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 86634

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  16 in total

1.  Killer cells induced by stimulation with allogeneic tumor cells and subsequent culture with recombinant interleukin-2.

Authors:  T Fukiage; H Murakami; M Eura; T Ikawa; T Ishikawa
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Auto-tumor lysis by blood lymphocytes in vitro. Strongly activated lymphocytes lack selectivity.

Authors:  F Vánky; E Klein
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  In vitro generation of effector cells cytotoxic to autologous targets from chronic myeloid leukemia patients in remission.

Authors:  R Somasundaram; S G Rao; S H Advani; S G Gangal
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 4.  Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.

Authors:  B M Vose
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Correlation between lymphocyte-mediated auto-tumor reactivities and the clinical course. II. Evaluation of 69 patients with lung carcinoma.

Authors:  F Vánky; A Péterffy; K Böök; J Willems; E Klein; G Klein
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  Lysis of fresh human tumour cells by autologous tumour-associated lymphocytes: two distinct types of autologous tumour killer cells induced by co-culture with autologous tumour.

Authors:  A Uchida; M Moore
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes.

Authors:  G Fossati; A Balsari; D Taramelli; M L Sensi; G Pellegris; M Nava; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

8.  Tumour-reactive lymphocytes stimulated in mixed lymphocyte and tumour culture. Clonal analysis of effector cells in cytotoxic and proliferative assays.

Authors:  B M Vose; W White
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  In vitro generation of tumour-specific lymphocyte reactivity to colonic carcinoma cells. Comparison with normal colonic mucosa cells.

Authors:  M Kuppner; S Wilkinson; E Casson; O Eremin
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

10.  Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture--no correlation with the postsurgical clinical course.

Authors:  F Vánky; E Klein; J Willems; K Böök; T Ivert; A Péterffy; U Nilsonne; A Kreicbergs
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.